Liraglutide Use in Prader-Willi Syndrome

NCT01542242 on ClinicalTrials.gov · last registry update 2015-12-09

Stopped early, having planned 1 participants. The sponsor logged completion for March 2013. Primary outcome, as filed: Hemoglobin A1C. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: TERMINATED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Vancouver General Hospital
Sponsor type: Other
Enrollment: 1
Started: 2012-02
Primary completion: 2013-03 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Hemoglobin A1C

Conditions studied

Diabetes Mellitus Type 2 · Prader Willi Syndrome

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.